Secondary dislipidemia in renal disease

1. Moorhead J, Chan MK, El-Nahas M et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2(8311): 1309–1311.

2. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291(4): 451–459.

3. Contreras G, Hu B, Astor BC et al. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol 2010; 21(12): 2131–2142.

4. Baigent C, Landray MJ, Reith C et al. [SHARP Investigators]. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181–2192.

5. März W, Genser B, Drechsler C et al. German Diabetes and Dialysis Study Investigators. Atorvastatin and low-- density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6(6): 1316–1325.

6. 6.Fellström BC, Jardine AG, Schmieder RE et al. [AURORA Study Group]. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360(14): 1395–1407.

7. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep 2013; 15(3): 340. Dostupné z DOI: <http://dx.doi.org/10.1007/s11886–012–0340–4>.

8. Cheung AK, Parker CJ, Ren K et al. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49(5): 1360–1371.

9. Speer T, Rohrer L, Blyszczuk P et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 2013; 38(4): 754–768.

10. Lacour B, Roullet JB, Liagre AM et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986; 8(6): 422–429.

11. Akmal M, Perkins S, Kasim SE et al. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis 1993; 22(1): 158–163.

12. Gaston RS, Kasiske BL, Fieberg AM et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9(8): 1811–1815.

13. Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 1992; 67(7): 653–657.

14. Moore R, Thomas D, Morgan E et al. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 1993; 25(1 Pt 2): 1060–1061.

15. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 Pt B): 2889–2934. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.11.002>. Erratum in J Am Coll Cardiol 2015; 66(24): 2812. J Am Coll Cardiol 2014; 63(25 Pt B): 3024–3025.

16. Mihaylova B, Emberson J, Blackwell L et al. [Cholesterol Treatment Trialists' (CTT) Collaborators]. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581–590.

17. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123(20): 2292–2333.

18. Wanner Ch, Tonelli M. [Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members]. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85(6): 1303–1309.

19. Inker LA, Astor BC, Fox CH et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the evaluation and management of CKD. Am J Kidney Dis 2014; 63(5): 713–735.

20. Bayer ND, Cochetti PT, Kumar MS et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90(8): 861–866.

21. Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 1992; 67(7): 653–657.

22. Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5(12): 2929–2936. Erratum in Am J Transplant 2006; 6(8): 1986.